Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Catalyst Pharmaceuticals management to meet virtually with Truist » 11:58
01/18/22
01/18
11:58
01/18/22
11:58
CPRX

Catalyst Pharmaceuticals

$6.02 /

-0.22 (-3.53%)

Virtual Meeting to be…

Virtual Meeting to be held on January 27 hosted by Truist.

ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$6.02 /

-0.22 (-3.53%)

CPRX Catalyst Pharmaceuticals
$6.02 /

-0.22 (-3.53%)

11/10/21 Piper Sandler
Piper Sandler ups Catalyst target to $7 given raising Firdapse estimates
09/30/21 Piper Sandler
Piper says Catalyst successful appeal should drive upside to Firdapse estimates
08/10/21 Piper Sandler
Catalyst Pharmaceuticals price target raised to $6.50 from $5.50 at Piper Sandler
05/12/21 Cantor Fitzgerald
Catalyst Pharmaceuticals price target raised to $11 from $8 at Cantor Fitzgerald
CPRX Catalyst Pharmaceuticals
$6.02 /

-0.22 (-3.53%)

CPRX Catalyst Pharmaceuticals
$6.02 /

-0.22 (-3.53%)

Conference/Events
Catalyst Pharmaceuticals management to meet virtually with Cantor Fitzgerald » 11:57
01/18/22
01/18
11:57
01/18/22
11:57
CPRX

Catalyst Pharmaceuticals

$5.99 /

-0.25 (-4.01%)

Virtual Meeting to be…

Virtual Meeting to be held on January 25 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$5.99 /

-0.25 (-4.01%)

CPRX Catalyst Pharmaceuticals
$5.99 /

-0.25 (-4.01%)

11/10/21 Piper Sandler
Piper Sandler ups Catalyst target to $7 given raising Firdapse estimates
09/30/21 Piper Sandler
Piper says Catalyst successful appeal should drive upside to Firdapse estimates
08/10/21 Piper Sandler
Catalyst Pharmaceuticals price target raised to $6.50 from $5.50 at Piper Sandler
05/12/21 Cantor Fitzgerald
Catalyst Pharmaceuticals price target raised to $11 from $8 at Cantor Fitzgerald
CPRX Catalyst Pharmaceuticals
$5.99 /

-0.25 (-4.01%)

CPRX Catalyst Pharmaceuticals
$5.99 /

-0.25 (-4.01%)

Over a week ago
Hot Stocks
Catalyst Pharmaceuticals announces court of appeals denial of Jacobus petition » 09:10
01/10/22
01/10
09:10
01/10/22
09:10
CPRX

Catalyst Pharmaceuticals

$6.55 /

-0.06 (-0.91%)

Catalyst Pharmaceuticals…

Catalyst Pharmaceuticals reported that the 11th Circuit Court of Appeals has denied Jacobus Pharmaceutical Company Inc.'s petition for rehearing of the 11th Circuit's prior ruling to overturn the U.S. Food and Drug Administration approval of Ruzurgi for pediatric patients with Lambert-Eaton myasthenic syndrome based on the orphan drug exclusivity of FIRDAPSE. Catalyst expects that the mandate to the District Court with instructions to enter summary judgment for Catalyst will be issued in the near future.

ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$6.55 /

-0.06 (-0.91%)

CPRX Catalyst Pharmaceuticals
$6.55 /

-0.06 (-0.91%)

11/10/21 Piper Sandler
Piper Sandler ups Catalyst target to $7 given raising Firdapse estimates
09/30/21 Piper Sandler
Piper says Catalyst successful appeal should drive upside to Firdapse estimates
08/10/21 Piper Sandler
Catalyst Pharmaceuticals price target raised to $6.50 from $5.50 at Piper Sandler
05/12/21 Cantor Fitzgerald
Catalyst Pharmaceuticals price target raised to $11 from $8 at Cantor Fitzgerald
CPRX Catalyst Pharmaceuticals
$6.55 /

-0.06 (-0.91%)

CPRX Catalyst Pharmaceuticals
$6.55 /

-0.06 (-0.91%)

Over a month ago
Hot Stocks
Catalyst Pharmaceuticals' marzeptacog alfa granted orphan status » 09:59
12/17/21
12/17
09:59
12/17/21
09:59
CPRX

Catalyst Pharmaceuticals

$6.89 /

+0.16 (+2.38%)

On December 15, the FDA…

On December 15, the FDA designated Catalyst Pharmaceuticals' marzeptacog alfa for orphan status as a treatment of bleeding episodes in patients with Hemophilia A or B, including those with inhibitors, according to a post to the agency's website. Reference Link

ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$6.89 /

+0.16 (+2.38%)

CPRX Catalyst Pharmaceuticals
$6.89 /

+0.16 (+2.38%)

11/10/21 Piper Sandler
Piper Sandler ups Catalyst target to $7 given raising Firdapse estimates
09/30/21 Piper Sandler
Piper says Catalyst successful appeal should drive upside to Firdapse estimates
08/10/21 Piper Sandler
Catalyst Pharmaceuticals price target raised to $6.50 from $5.50 at Piper Sandler
05/12/21 Cantor Fitzgerald
Catalyst Pharmaceuticals price target raised to $11 from $8 at Cantor Fitzgerald
CPRX Catalyst Pharmaceuticals
$6.89 /

+0.16 (+2.38%)

CPRX Catalyst Pharmaceuticals
$6.89 /

+0.16 (+2.38%)

Hot Stocks
Catalyst Pharmaceuticals announces DyDo initiation of Phase 3 study of FIRDAPSE » 07:03
12/06/21
12/06
07:03
12/06/21
07:03
CPRX

Catalyst Pharmaceuticals

$6.86 /

-0.19 (-2.70%)

Catalyst Pharmaceuticals…

Catalyst Pharmaceuticals announced that its collaboration partner DyDo Pharma has initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of Catalyst's FIRDAPSE 10 mg tablets for the treatment of Lambert-Eaton myasthenic syndrome. Catalyst entered into a sub-license agreement with DyDo to develop and commercialize FIRDAPSE in Japan in June 2021. Under the terms of the agreement, Catalyst will provide clinical and commercial supply to DyDo and technical support to obtain regulatory approval for the product from the Japanese regulatory authorities. DyDo is responsible for the development and commercialization of the product in Japan pending regulatory approval, and Catalyst will be entitled to development and sales milestones and revenue for clinical and commercial supply of the product.

ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$6.86 /

-0.19 (-2.70%)

CPRX Catalyst Pharmaceuticals
$6.86 /

-0.19 (-2.70%)

11/10/21 Piper Sandler
Piper Sandler ups Catalyst target to $7 given raising Firdapse estimates
09/30/21 Piper Sandler
Piper says Catalyst successful appeal should drive upside to Firdapse estimates
08/10/21 Piper Sandler
Catalyst Pharmaceuticals price target raised to $6.50 from $5.50 at Piper Sandler
05/12/21 Cantor Fitzgerald
Catalyst Pharmaceuticals price target raised to $11 from $8 at Cantor Fitzgerald
CPRX Catalyst Pharmaceuticals
$6.86 /

-0.19 (-2.70%)

CPRX Catalyst Pharmaceuticals
$6.86 /

-0.19 (-2.70%)

Recommendations
Piper Sandler ups Catalyst target to $7 given raising Firdapse estimates » 11:34
11/10/21
11/10
11:34
11/10/21
11:34
CPRX

Catalyst Pharmaceuticals

$6.47 /

+0.29 (+4.69%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Catalyst Pharmaceuticals to $7 from $6.50 and keeps an Overweight rating on the shares after the company reported Q3 earnings and provided a pipeline update. The analyst notes that U.S. Firdapse revenues of $35.9M were up 7% quarter-over-quarter driven by new patient enrollment, continued favorable reimbursement dynamics and stable discontinuation rates. Catalyst expects this organic growth driven by new patient enrollments to continue for the foreseeable future, Catanzaro adds. Overall, the business continues to generate cash flow, and the company will look to leverage its cash position to diversify its pipeline through business development activities, the analyst highlights.

ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$6.47 /

+0.29 (+4.69%)

CPRX Catalyst Pharmaceuticals
$6.47 /

+0.29 (+4.69%)

09/30/21 Piper Sandler
Piper says Catalyst successful appeal should drive upside to Firdapse estimates
08/10/21 Piper Sandler
Catalyst Pharmaceuticals price target raised to $6.50 from $5.50 at Piper Sandler
05/12/21 Cantor Fitzgerald
Catalyst Pharmaceuticals price target raised to $11 from $8 at Cantor Fitzgerald
05/11/21 Piper Sandler
Piper Sandler remains bullish on Catalyst following Q1 results, pipeline update
CPRX Catalyst Pharmaceuticals
$6.47 /

+0.29 (+4.69%)

CPRX Catalyst Pharmaceuticals
$6.47 /

+0.29 (+4.69%)

Earnings
Catalyst Pharmaceuticals reports Q3 adjusted EPS 14c, consensus 10c » 16:32
11/09/21
11/09
16:32
11/09/21
16:32
CPRX

Catalyst Pharmaceuticals

$6.18 /

-0.12 (-1.90%)

Reports Q3 revenue…

Reports Q3 revenue $35.9M, consensus $34.59M. "We delivered another quarter of strong financial results while making important progress on all fronts," said Patrick McEnany, Chairman and CEO of Catalyst. "We reported a record quarter for net sales for FIRDAPSE, further underscoring the strength of our commercial capabilities while advancing our efforts in support of the orphan drug exclusivity of FIRDAPSE for the treatment of LEMS. We continued to execute on all key growth initiatives, including plans to expand the label for FIRDAPSE to include all LEMS patients, including the very few pediatric patients diagnosed with LEMS. Our quarterly achievements demonstrate continued performance excellence supported by several key strategic decisions that have positioned Catalyst firmly for the future. In saying that, we are excited about the path ahead as we continue to execute across all fronts to drive sustainable growth for the long term."

ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$6.18 /

-0.12 (-1.90%)

CPRX Catalyst Pharmaceuticals
$6.18 /

-0.12 (-1.90%)

09/30/21 Piper Sandler
Piper says Catalyst successful appeal should drive upside to Firdapse estimates
08/10/21 Piper Sandler
Catalyst Pharmaceuticals price target raised to $6.50 from $5.50 at Piper Sandler
05/12/21 Cantor Fitzgerald
Catalyst Pharmaceuticals price target raised to $11 from $8 at Cantor Fitzgerald
05/11/21 Piper Sandler
Piper Sandler remains bullish on Catalyst following Q1 results, pipeline update
CPRX Catalyst Pharmaceuticals
$6.18 /

-0.12 (-1.90%)

CPRX Catalyst Pharmaceuticals
$6.18 /

-0.12 (-1.90%)

Over a quarter ago
Recommendations
Piper says Catalyst successful appeal should drive upside to Firdapse estimates » 14:39
09/30/21
09/30
14:39
09/30/21
14:39
CPRX

Catalyst Pharmaceuticals

$5.38 /

+0.36 (+7.17%)

While Piper Sandler…

While Piper Sandler analyst Joseph Catanzaro had always leaned toward the courts siding with the FDA given prior precedent, it was announced that the 11th Circuit Court of Appeals ruled in favor of Catalyst Pharmaceuticals and its legal challenge around the FDA's decision to approve competitor Ruzurgi. As such, any patient currently receiving Ruzurgi would be expected to switch over to Firdapse. The analyst believes this will no doubt provide some upside around near- and maybe long-term Firdapse estimates, but to what degree is difficult to say given the limited visibility into Ruzurgi's usage. Catanzaro sees this as a clearly favorable outcome, and keeps an Overweight rating and a price target of $6.50.

ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$5.38 /

+0.36 (+7.17%)

CPRX Catalyst Pharmaceuticals
$5.38 /

+0.36 (+7.17%)

08/10/21 Piper Sandler
Catalyst Pharmaceuticals price target raised to $6.50 from $5.50 at Piper Sandler
05/12/21 Cantor Fitzgerald
Catalyst Pharmaceuticals price target raised to $11 from $8 at Cantor Fitzgerald
05/11/21 Piper Sandler
Piper Sandler remains bullish on Catalyst following Q1 results, pipeline update
03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
CPRX Catalyst Pharmaceuticals
$5.38 /

+0.36 (+7.17%)

CPRX Catalyst Pharmaceuticals
$5.38 /

+0.36 (+7.17%)

Hot Stocks
Catalyst Pharmaceuticals trading resumes  12:40
09/30/21
09/30
12:40
09/30/21
12:40
CPRX

Catalyst Pharmaceuticals

$5.42 /

+0.4 (+7.97%)

 
ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$5.42 /

+0.4 (+7.97%)

CPRX Catalyst Pharmaceuticals
$5.42 /

+0.4 (+7.97%)

08/10/21 Piper Sandler
Catalyst Pharmaceuticals price target raised to $6.50 from $5.50 at Piper Sandler
05/12/21 Cantor Fitzgerald
Catalyst Pharmaceuticals price target raised to $11 from $8 at Cantor Fitzgerald
05/11/21 Piper Sandler
Piper Sandler remains bullish on Catalyst following Q1 results, pipeline update
03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
CPRX Catalyst Pharmaceuticals
$5.42 /

+0.4 (+7.97%)

CPRX Catalyst Pharmaceuticals
$5.42 /

+0.4 (+7.97%)

Hot Stocks
Catalyst Pharmaceuticals to resume trading at 12:40 pm ET » 12:13
09/30/21
09/30
12:13
09/30/21
12:13
CPRX

Catalyst Pharmaceuticals

$5.42 /

+0.4 (+7.97%)

Catalyst Pharmaceuticals…

Catalyst Pharmaceuticals is scheduled to resume trading at 12:40 pm ET, with quotation set to resume at 12:35 pm ET, according to Nasdaq.

ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$5.42 /

+0.4 (+7.97%)

CPRX Catalyst Pharmaceuticals
$5.42 /

+0.4 (+7.97%)

08/10/21 Piper Sandler
Catalyst Pharmaceuticals price target raised to $6.50 from $5.50 at Piper Sandler
05/12/21 Cantor Fitzgerald
Catalyst Pharmaceuticals price target raised to $11 from $8 at Cantor Fitzgerald
05/11/21 Piper Sandler
Piper Sandler remains bullish on Catalyst following Q1 results, pipeline update
03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
CPRX Catalyst Pharmaceuticals
$5.42 /

+0.4 (+7.97%)

CPRX Catalyst Pharmaceuticals
$5.42 /

+0.4 (+7.97%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.